NVX-CoV-2601

N/A

Report date: 2023/10/09 11:47:25

Base Information

Drug NameNVX-CoV-2601
Drug Alias NameSARS-CoV-2 rS Variant VaccinesNVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccineXBB.1.5 VaccineOmicron sub variant XBB.1.5 vaccineOmicron sub variant XBB.1.5 SARS-CoV-2 rS +[8] 
ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/10/03
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovavax
China Registration ClassN/A

Develop Information

Active CompaniesNovavax
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A